Search

everythinglearnresearchcommunity

for

Search:↓

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

EX104 shows promise in treating hair loss by promoting hair growth and improving scalp health.

Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Some dibenzo compounds might help treat cancer with fewer side effects.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

The FDA approved a new Pfizer drug for hair loss in teens.

AH-001 could be a safer and more effective treatment for hair loss.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.

Minoxidil caused a severe rash in a patient, which improved after stopping the drug.